Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Dolutegravir Plus Lamivudine in HIV-1 Infected Adults Who Are Virologically Suppressed

Trial Profile

A Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Dolutegravir Plus Lamivudine in HIV-1 Infected Adults Who Are Virologically Suppressed

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dolutegravir/lamivudine (Primary) ; Tenofovir alafenamide
  • Indications HIV-1 infections
  • Focus Registrational; Therapeutic Use
  • Acronyms TANGO
  • Sponsors ViiV Healthcare
  • Most Recent Events

    • 16 Oct 2019 According to a ViiV Healthcare media release, supplemental New Drug Application to the US Food and Drug Administration (FDA) for Dovato (dolutegravir and lamivudine) as a switch treatment for HIV-1 infection in virologically suppressed adults on a stable antiretroviral regimen with no treatment failure, has been submitted.The filing is based on the results from this study.
    • 24 Jul 2019 Full trial results published in the ViiV Healthcare media release
    • 10 Jul 2019 According to a ViiV Healthcare media release, full results from the study will be presented at the 10th International AIDS Society Conference on HIV Science (IAS 2019, 21st-24th July 2019 in Mexico City).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top